LinkedIn Profile

Access Xcovery historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:xcovery 647976 Dec 3rd, 2020 12:00AM Xcovery 694 20.00 Open Biotechnology Dec 3rd, 2020 03:30PM Dec 3rd, 2020 03:30PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Xcovery Health Care Health Care Equipment & Services
private:xcovery 647976 Dec 2nd, 2020 12:00AM Xcovery 694 20.00 Open Biotechnology Dec 2nd, 2020 05:17PM Dec 2nd, 2020 05:17PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Xcovery Health Care Health Care Equipment & Services
private:xcovery 647976 Dec 1st, 2020 12:00AM Xcovery 695 20.00 Open Biotechnology Dec 1st, 2020 03:54PM Dec 1st, 2020 03:54PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Xcovery Health Care Health Care Equipment & Services
private:xcovery 647976 Nov 30th, 2020 12:00AM Xcovery 694 20.00 Open Biotechnology Nov 29th, 2020 09:49PM Nov 30th, 2020 06:48PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Xcovery Health Care Health Care Equipment & Services
private:xcovery 647976 Nov 28th, 2020 12:00AM Xcovery 694 20.00 Open Biotechnology Nov 28th, 2020 05:22PM Nov 28th, 2020 05:22PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Xcovery Health Care Health Care Equipment & Services
private:xcovery 647976 Nov 27th, 2020 12:00AM Xcovery 694 19.00 Open Biotechnology Nov 27th, 2020 01:49PM Nov 27th, 2020 01:49PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Xcovery Health Care Health Care Equipment & Services
private:xcovery 647976 Nov 26th, 2020 12:00AM Xcovery 694 19.00 Open Biotechnology Nov 25th, 2020 08:58PM Nov 25th, 2020 08:58PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Xcovery Health Care Health Care Equipment & Services
private:xcovery 647976 Nov 24th, 2020 12:00AM Xcovery 694 19.00 Open Biotechnology Nov 24th, 2020 04:32PM Nov 24th, 2020 04:32PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Xcovery Health Care Health Care Equipment & Services
private:xcovery 647976 Nov 23rd, 2020 12:00AM Xcovery 694 19.00 Open Biotechnology Nov 23rd, 2020 06:21PM Nov 23rd, 2020 06:21PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Xcovery Health Care Health Care Equipment & Services
private:xcovery 647976 Nov 22nd, 2020 12:00AM Xcovery 693 19.00 Open Biotechnology Nov 21st, 2020 07:06PM Nov 22nd, 2020 05:17PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Xcovery Health Care Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.